TLX
Telix Pharmaceuticals Limited American Depositary Shares
About: Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
Employees: 554
0
Funds holding %
of 7,245 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
1,290% more capital invested
Capital invested by funds: $57.4K [Q4 2024] → $799K (+$741K) [Q1 2025]
500% more funds holding
Funds holding: 1 [Q4 2024] → 6 (+5) [Q1 2025]
0.01% more ownership
Funds ownership: 0% [Q4 2024] → 0.01% (+0.01%) [Q1 2025]
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Research analyst outlook
We haven’t received any recent analyst ratings for TLX.
Financial journalist opinion
Based on 11 articles about TLX published over the past 30 days
Positive
Seeking Alpha
1 week ago
Telix Pharmeceuticals: Imaging Biomarkers Paving The Way For Theranostics
Telix Pharmaceuticals excels in radiopharmaceuticals, with strong revenue growth driven by imaging products like Illuccix and promising therapeutic programs in development. TLX's key imaging projects include Gozellix and Illuccix for prostate cancer, with developmental programs targeting kidney and brain cancers. Therapeutic pipeline highlights include TLX591 for prostate cancer and TLX252 for kidney cancer, with significant progress in clinical trials.
Neutral
GlobeNewsWire
2 weeks ago
Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy
MELBOURNE, Australia and INDIANAPOLIS, May 08, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its Fibroblast Activation Protein (FAP)-targeting therapy candidate, TLX400, has been published in Thyroid, the official journal of the American Thyroid Association. The candidate demonstrated an encouraging safety profile and efficacy in aggressive, radioiodine-resistant (RAI-R) thyroid cancer1.
Neutral
Accesswire
2 weeks ago
Shareholders that Lost Money on Telix Pharmaceuticals Limited (TLX) Should Contact Levi & Korsinsky About Securities Fraud Investigation - TLX
NEW YORK, NY / ACCESS Newswire / May 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Telix Pharmaceuticals Limited ("Telix Pharmaceuticals Limited") (NASDAQ:TLX) concerning possible violations of federal securities laws. On April 28, 2025, Telix issued a press release announcing that the FDA issued a Complete Response Letter denying approval of Telix's New Drug Application for TLX101-CDx ("Pixclara").
Neutral
Accesswire
2 weeks ago
ATTENTION Telix Pharmaceuticals Limited Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESS Newswire / May 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Telix Pharmaceuticals Limited ("Telix Pharmaceuticals Limited") (NASDAQ:TLX) concerning possible violations of federal securities laws. On April 28, 2025, Telix issued a press release announcing that the FDA issued a Complete Response Letter denying approval of Telix's New Drug Application for TLX101-CDx ("Pixclara").
Neutral
Accesswire
2 weeks ago
Telix Pharmaceuticals Limited INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Telix Pharmaceuticals Limited (TLX)
NEW YORK, NY / ACCESS Newswire / May 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Telix Pharmaceuticals Limited ("Telix Pharmaceuticals Limited") (NASDAQ:TLX) concerning possible violations of federal securities laws. On April 28, 2025, Telix issued a press release announcing that the FDA issued a Complete Response Letter denying approval of Telix's New Drug Application for TLX101-CDx ("Pixclara").
Neutral
Accesswire
2 weeks ago
Telix Pharmaceuticals Limited INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Telix Pharmaceuticals Limited (TLX)
NEW YORK, NY / ACCESS Newswire / May 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Telix Pharmaceuticals Limited ("Telix Pharmaceuticals Limited") (NASDAQ:TLX) concerning possible violations of federal securities laws. On April 28, 2025, Telix issued a press release announcing that the FDA issued a Complete Response Letter denying approval of Telix's New Drug Application for TLX101-CDx ("Pixclara").
Neutral
Accesswire
3 weeks ago
TLX STOCK ALERT: Levi & Korsinsky Notifies Telix Pharmaceuticals Limited Investors of an Ongoing Investigation
NEW YORK, NY / ACCESS Newswire / May 1, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Telix Pharmaceuticals Limited ("Telix Pharmaceuticals Limited") (NASDAQ:TLX) concerning possible violations of federal securities laws. On April 28, 2025, Telix issued a press release announcing that the FDA issued a Complete Response Letter denying approval of Telix's New Drug Application for TLX101-CDx ("Pixclara").
Neutral
Accesswire
3 weeks ago
TLX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Telix Pharmaceuticals Limited
NEW YORK, NY / ACCESS Newswire / April 30, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Telix Pharmaceuticals Limited ("Telix Pharmaceuticals Limited") (NASDAQ:TLX) concerning possible violations of federal securities laws. On April 28, 2025, Telix issued a press release announcing that the FDA issued a Complete Response Letter denying approval of Telix's New Drug Application for TLX101-CDx ("Pixclara").
Neutral
GlobeNewsWire
3 weeks ago
Telix's Illuccix PSMA-PET Imaging Agent Approved in France
New approval provides French hospitals and clinics with access to a proven PSMA-PET imaging agent New approval provides French hospitals and clinics with access to a proven PSMA-PET imaging agent
Neutral
Accesswire
3 weeks ago
Levi & Korsinsky Announces an Investigation on Behalf of Telix Pharmaceuticals Limited (TLX) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESS Newswire / April 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Telix Pharmaceuticals Limited ("Telix Pharmaceuticals Limited") (NASDAQ:TLX) concerning possible violations of federal securities laws. On April 28, 2025, Telix issued a press release announcing that the FDA issued a Complete Response Letter denying approval of Telix's New Drug Application for TLX101-CDx ("Pixclara").
Charts implemented using Lightweight Charts™